These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 8609615)

  • 1. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
    Laisney IL; Benjamin H; Gefter M; Strosberg AD
    Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2.
    Juárez-González VR; Riaño-Umbarila L; Quintero-Hernández V; Olamendi-Portugal T; Ortiz-León M; Ortíz E; Possani LD; Becerril B
    J Mol Biol; 2005 Mar; 346(5):1287-97. PubMed ID: 15713481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
    Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for distinct contributions of heavy and light chains to restriction of antibody recognition of the HIV-1 principal neutralization determinant.
    Watkins BA; Davis AE; Fiorentini S; di Marzo Veronese F; Reitz MS
    J Immunol; 1996 Feb; 156(4):1676-83. PubMed ID: 8568275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.
    VanCott TC; Bethke FR; Polonis VR; Gorny MK; Zolla-Pazner S; Redfield RR; Birx DL
    J Immunol; 1994 Jul; 153(1):449-59. PubMed ID: 7515931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation.
    Figini M; Marks JD; Winter G; Griffiths AD
    J Mol Biol; 1994 May; 239(1):68-78. PubMed ID: 8196048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.